Quick Answer
Sensei Biotherapeutics, Inc. reported Cash and Equivalents of $8.67 million for fiscal year 2025.
Sensei Biotherapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.67M | -13.3% |
| 2024 | $9.99M | -23.2% |
| 2023 | $13.01M | -26.9% |
| 2022 | $17.80M | +148.6% |
| 2021 | $7.16M | -56.9% |
| 2020 | $16.60M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.56M | -44.8% | -15.9% |
| June 30, 2025 | $12.56M | +5.6% | +27.1% |
| March 31, 2025 | $9.88M | -9.8% | -1.2% |
| December 31, 2024 | $9.99M | -23.2% | -47.8% |
| September 30, 2024 | $19.13M | +68.7% | +60.9% |
| June 30, 2024 | $11.89M | +16.3% | +8.5% |
| March 31, 2024 | $10.96M | +35.1% | -15.8% |
| December 31, 2023 | $13.01M | -26.9% | +14.7% |
- Sensei Biotherapeutics, Inc. showed a decrease of -13.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Sensei Biotherapeutics, Inc.’s cash and equivalents has declined by 47.8% (from $16.60 million to $8.67 million).
- The most recent figure is from Sensei Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: